Your session is about to expire
← Back to Search
Ipilimumab for Multiple Myeloma
Study Summary
This trial will test the safety of ipilimumab as maintenance therapy for people with relapsed/refractory multiple myeloma who have received chemotherapy and allogeneic hematopoietic stem cell transplant.
- Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 3 trial • 1289 Patients • NCT01285609Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is it possible to join this medical experiment?
"This trial seeks 45 individuals with relapsed or refractory multiple myeloma, aged 21 to 73 years old. To be considered for the study, potential participants must qualify by meeting these criteria: fall between two lines of therapy and eligible for CD34-selected HSCT according to MSKCC adult BMT guidelines; have a 10/10 matched donor; age over 21 but under 73; and diagnose as having at least 2 prior therapies leading to very good partial remission in most recent salvage therapy."
Are there a multitude of locations administering this experiment in the city?
"Presently, 7 medical centers are involved in administering this trial. Such venues include Memorial Sloan Kettering Commack (Limited Protocol Activities) in Commack and Harrison's Memorial Sloan Kettering Westchester (Limited Protocol Activities), as well as Montvale's Memorial Sloan Kettering Bergen (Limited Protocol Activities). There are also 4 other sites taking part."
What other medical tests have been conducted with Ipilimumab?
"Currently, there are 318 ongoing trials for Ipilimumab. 38 of these clinical studies have attained Phase 3 status and take place primarily in Pittsburgh, Pennsylvania; however, 20362 research centres around the world are running their own investigations on this treatment."
How many individuals are being enrolled in this medical research?
"Affirmative. As per the information on clinicaltrials.gov, this research project is currently looking for participants and was initially posted on November 12th 2020 with its latest update occurring on January 21st 2022. It requires 45 patients from 7research sites to complete their study."
How is Ipilimumab typically utilized to assist in patient treatment?
"Ipilimumab is a common therapy for cutaneous melanoma, and it also has efficacy when treating conditions such as complete resection, liver carcinoma, and metastatic melanoma."
Is this study recruiting participants at the present time?
"Affirmative. According to clinicaltrials.gov, this trial launched on November 12th 2020 and is actively searching for participants. A total of 45 patients will be recruited across 7 different sites."
Is this research endeavor open to those who have attained the age of twenty or above?
"Patients that meet the qualifications for this clinical trial need to be between 21 and 73 years old. Additionally, there are 59 trials available specifically designed for minors while 1108 have been created with elderly individuals in mind."
Share this study with friends
Copy Link
Messenger